SciELO - Scientific Electronic Library Online

 
vol.24 issue5Mechanical complications of acute myocardial infarction: common but potentially fatalsarcoidosis cardiaca primaria Ventricular arrhythmias as a first sign of primary cardiac sarcoidosis author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Colombiana de Cardiología

Print version ISSN 0120-5633

Abstract

DUQUE, Mauricio; GAVIRIA, María C.; GONZALEZ, Juanita  and  GALLO, Juan E.. con anti-PCSK9 Heterozygous familial hypercholesterolaemia being managed with anti-PCSK9. Rev. Colomb. Cardiol. [online]. 2017, vol.24, n.5, pp.510-510.  Epub June 27, 2017. ISSN 0120-5633.  http://dx.doi.org/10.1016/j.rccar.2017.03.002.

Introduction:

Familial hypercholesterolaemia is a substantial risk factor for suffering premature coronary, peripheral arterial, and valular disease. There are two forms described, depending on their genetics and zygosity, as well as three associated genetic mutations. Although treatment with statins is considered first line, some patients do not reach targets, as such that that PCSK9 inhibitors have been used as a new strategy.

Materials and method:

A case is presented of a 42 year-old patient with heterozygous familial hypercholesterolaemia treated with PCSK9 inhibitors. The criteria and genetic studies used to make a diagnosis are described, as well as the chronology of the treatments that have been received and the laboratory results before and after starting with evolocumab. A review has also been made of the subject of familial hypercholesterolaemia and its treatment with PCSK9 inhibitors.

Conclusions:

Familial hypercholesterolaemia is a diseases that may have serious cardiovascular consequences. PCSK9 inhibitors have become a promising alternative for those who do not respond to conventional therapies. Studies are required that can corroborate or contradict the benefits and adverse effects found up until now in patients subjected to these new therapies in order to offer an ideal and appropriate treatment.

Keywords : Familial hypercholesterolaemia; Cardiovascular disease; Coronary disease; Inhibitors.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )